Study of Ziltivekimab Versus Placebo on Coronary Artery Disease After Heart Attack Using Advanced Imaging Effects on Artery Plaques and Heart Health Over 15 Months

What this Trial Is About

Researchers are investigating whether a new medication called ziltivekimab can help improve artery health in patients with coronary artery disease CAD who have recently had a heart attack acute myocardial infarction. Despite existing treatments, many patients remain at risk for further heart attacks and hospitalizations. This study focuses on the role of inflammation in artery blockages and aims to see if reducing inflammation with ziltivekimab affects the buildup and characteristics of plaques in the coronary arteries. The study is a randomized, double-blind, placebo-controlled trial where participants receive either ziltivekimab or a placebo through a once-monthly injection under the skin, in addition to their standard heart attack treatments. The first dose is given as soon as possible, no later than 48 hours after a heart procedure called PCI. The treatment lasts for about one year. Advanced imaging techniques like intravascular ultrasound, near-infrared spectroscopy, and optical coherence tomography will be used to examine changes in the arteries and plaque composition over time. During the approximately 15-month study period, participants will undergo regular assessments including imaging scans of their coronary arteries to measure plaque volume, lipid content, and fibrous cap thickness. Researchers will monitor changes from the start of treatment to the end of the study. Safety will be closely observed, and participants will continue to receive their usual care alongside the study treatment. The main goal is to determine if ziltivekimab can reduce artery narrowing and stabilize plaques to lower the risk of future heart problems.

Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction